AC
NGNE icon

Ascend Capital’s Neurogene NGNE Stock Holding History

Ascend Capital’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,810
Closed -$2.54M – 251
2017
Q4 		$2.54M Buy
10,810
+85
+0.8% +$19.9K 0.1% 162
2017
Q3 		$3.04M Buy
10,725
+9
+0.1% +$2.58K 0.11% 124
2017
Q2 		$3.02M Buy
+10,716
New +$3.07M 0.14% 125

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ascend Capital's NGNE Position: Q1 2018 in Review

Ascend Capital sold out of Neurogene (NGNE) in Q1 2018, closing a stake of 10,810 shares — an estimated $2.54M sold.

Ascend Capital first reported a position in NGNE in Q2 2017 and held it in 3 quarters. The position peaked at $3.04M in Q3 2017. 50 funds tracked by Wall St. Rank hold NGNE as of Q1 2018.

  • Ascend Capital reported no remaining Neurogene position as of Q1 2018 after selling out during the quarter.
  • Ascend Capital sold 10,810 Neurogene shares in Q1 2018, an estimated $2.54M.
  • Ascend Capital first reported a position in Neurogene in Q2 2017 and held it in 3 quarters.
  • Ascend Capital's Neurogene position peaked at $3.04M in Q3 2017.
  • 50 funds tracked by Wall St. Rank held Neurogene as of Q1 2018.

Based on Ascend Capital's 13F filing for Q1 2018, filed 14 May 2018.